Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

IDF00045

Sigma-Aldrich

2,2′-Dihydroxychalcone

AldrichCPR

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C15H12O3
CAS Number:
15131-80-3
Molecular Weight:
240.25
MDL number:
MFCD00017715
UNSPSC Code:
12352200
PubChem Substance ID:
329815515
Pricing and availability is not currently available.

form

solid

SMILES string

Oc1ccccc1\C=C\C(=O)c2ccccc2O

InChI

1S/C15H12O3/c16-13-7-3-1-5-11(13)9-10-15(18)12-6-2-4-8-14(12)17/h1-10,16-17H/b10-9+

InChI key

KSHCTKZLHCSARH-MDZDMXLPSA-N

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
GF43011391GF09165786GF02373869
Lanthanum foil, 100x100mm, thickness 0.1mm, as rolled, 99%

GF15415691

Lanthanum

Lanthanum foil, 100x100mm, thickness 0.125mm, as rolled, 99%

GF43011391

Lanthanum

Lanthanum foil, 25x25mm, thickness 0.1mm, as rolled, 99%

GF09165786

Lanthanum

Lanthanum lump, 25 mm max. lump size, weight 50 g, purity 99%

GF02373869

Lanthanum

form

foil

form

foil

form

foil

form

lumps

manufacturer/tradename

Goodfellow 154-156-91

manufacturer/tradename

Goodfellow 430-113-91

manufacturer/tradename

Goodfellow 091-657-86

manufacturer/tradename

Goodfellow 023-738-69

assay

99%

assay

99%

assay

≥99%

assay

99%

density

6.19 g/mL at 25 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

density

6.19 g/mL at 25 °C (lit.)

mp

920 °C (lit.)

mp

920 °C (lit.)

mp

920 °C (lit.)

mp

920 °C (lit.)

bp

3464 °C (lit.)

bp

3464 °C (lit.)

bp

3464 °C (lit.)

bp

3464 °C (lit.)

Other Notes

Please note that Sigma-Aldrich provides this product to early discovery researchers as part of a collection of unique chemicals. Sigma-Aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final.

NOTWITHSTANDING ANY CONTRARY PROVISION CONTAINED IN SIGMA-ALDRICH′S STANDARD TERMS AND CONDITIONS OF SALE OR AN AGREEMENT BETWEEN SIGMA-ALDRICH AND BUYER, SIGMA-ALDRICH SELLS THIS PRODUCT "AS-IS" AND MAKES NO REPRESENTATION OR WARRANTY WHATSOEVER WITH RESPECT TO THIS PRODUCT, INCLUDING ANY (A) WARRANTY OF MERCHANTABILITY; (B) WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE; OR (C) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY; WHETHER ARISING BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

Legal Information

Product of Indofine

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Marc E De Broe
Seminars in dialysis, 21(2), 142-144 (2008-02-06)
The recent recognition of gadolinium (Gd) administration as a cause of nephrogenic systemic fibrosis (NSF) is a growing concern. The similarity of Gd and lanthanum (La), based on their place in the table of Mendeljev, has led to assumptions that
Tilman B Drüeke
Seminars in dialysis, 20(4), 329-332 (2007-07-20)
Controlling serum phosphorus levels in patients with renal failure is critical. The use of oral phosphate-binding agents is universal for patients with end-stage kidney disease to reduce phosphate absorption. The therapeutic goal is to reduce serum phosphorus levels without disturbing
M Cozzolino et al.
The International journal of artificial organs, 30(4), 293-300 (2007-05-24)
Phosphate overload is a dramatic consequence in end-stage renal disease (ESRD) patients. Recent studies have well documented that abnormalities in mineral and bone metabolism in these patients are associated with increased cardiovascular morbidity and mortality. Elevated serum phosphate and calcium-phosphate
Gadolinium and lanthanum: a iatrogenic transmetallation?
Simona Brambilla et al.
Clinical biochemistry, 41(13), 1029-1033 (2008-06-19)
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service